Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma... | NCT00398177

Studies
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

NCT00398177

Sponsor

Stanford University

Status

Recruiting

Last Update Posted

Dec 24, 2025Actual

Enrollment

9,999Estimated

Phase

Not provided

Conditions

Lymphoma, Non-Hodgkin
Hodgkin's Disease

Interventions

Not provided

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

ID	Type	Description
76973	Other Identifier	Stanford University Alternate IRB Approval Number
LYM0001	Other Identifier	OnCore
IRB-13500	Other Identifier	Stanford IRB

Status Module

Record Verification Date

Dec 2025

Overall Recruitment Status or Expanded Access Status

Recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Jan 1999

Primary Completion Date

Jan 2099Estimated

Completion Date

Jan 2099Estimated

First Submitted Date

Nov 9, 2006

First Submission Date that Met QC Criteria

Nov 9, 2006

First Posted Date

Nov 10, 2006Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Dec 17, 2025

Last Update Posted Date

Dec 24, 2025Actual

Name	Class
The Leukemia and Lymphoma Society	OTHER
Biospect Inc	INDUSTRY

Oversight Module

Has Data Monitoring Committee (DMC)

Yes

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The purpose of this study is to characterize the molecular and cell biology of the tumor cells in lymphoma.

Detailed Description

This research involves the study of lymphoma cells in order to better understand how the disease grows and spreads. This study may lead to the development of special materials that could be used, in the future, to treat lymphoma or to follow the response of lymphoma to treatment.

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

Retention

Enrollment

9,999Estimated

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Collection of tumor tissue to characterize the molecular and cell biology of tumor cells in lymphoma.		The study will continue indefinitely.

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Diagnosis of Hodgkin's disease or non-Hodgkin's lymphoma, any cellular classification, any stage, any grade.
Adult or pediatric patients receiving lymph node excision for purposes other than cancer therapy (i.e. tonsillectomy, sleep apnea).
A routine procedure for tissue collection is planned.
Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

Patients without NHL or Hodgkin's disease

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Any type of NHL or Hodgkin's disease.

Sampling Method

Non-Probability Sample

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
Alyssa M Kanegai	Contact	650-736-1596		akanegai@stanford.edu

Overall Officials

Name	Affiliation	Role
Ronald Levy, MD	Stanford University	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Stanford University School of Medicine	Recruiting	Stanford	California	94305	United States

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
40802906	Derived	Roschewski M, Kurtz DM, Westin JR, Lynch RC, Gopal AK, Alig SK, Sworder BJ, Cherng HJ, Kuffer C, Blair D, Brown K, Goldstein JS, Schultz A, Close S, Chabon JJ, Diehn M, Wilson WH, Alizadeh AA. Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. J Clin Oncol. 2025 Dec;43(34):3652-3661. doi: 10.1200/JCO-25-01534. Epub 2025 Aug 13.
30125215

ID	Term
D008228	Lymphoma, Non-Hodgkin
D006689	Hodgkin Disease

ID	Term
D008223	Lymphoma
D009370	Neoplasms by Histologic Type
D009369	Neoplasms
D008232	Lymphoproliferative Disorders